Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoflurane versus intravenous sedation for mechanically ventilated COVID-19 ARDS
NL-OMON27812Not yet recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Apr 2020
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of isoflurane in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Change in PaO2/FiO2 ratio, Change in oxygenation index and 1 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
isoflurane
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NL-OMON27812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27812.